skip to main content

Pill-in-the-Pocket Effectiveness — EECC MCQ

Instant feedback + full explanation. One question, done properly.

EasyArrhythmia & ElectrophysiologyPill-in-the-Pocket EffectivenessEECC

A 55-year-old man with paroxysmal AF takes flecainide 200 mg as a 'pill-in-the-pocket' dose at the onset of an AF episode. He also takes bisoprolol 5 mg daily as a rate-limiting agent. After 4 hours, his AF terminates. How effective is the pill-in-the-pocket strategy and for which patients is it appropriate?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Use supervised pill-in-the-pocket therapy in selected patients

The pill-in-the-pocket (PIP) approach per the 2024 ESC AF Guidelines: a single oral dose of flecainide (200-300 mg) or propafenone (450-600 mg) taken by the patient at the onset of AF symptoms, aiming for self-cardioversion outside hospital. Effectiveness: 50-80% conversion to sinus rhythm within 2-6 hours. Prerequisites: (1) no structural heart disease (no HFrEF, no significant LVH, no CAD); (2) infrequent episodes (not daily AF); (3) haemodynamically well-tolerated AF episodes; (4) first dose MUST be supervised (in hospital/clinic) to monitor for proarrhythmia (1:1 atrial flutter, QRS widening, hypotension); (5) concomitant rate-limiting agent (beta-blocker or diltiazem — to prevent 1:1 flutter conduction); (6) patient education on when to call for help (persistent rapid palpitations, chest pain, presyncope). PIP empowers patients and reduces emergency department visits.

Reference: ESC (2024): AF Guidelines: https://bnf.nice.org.uk/